ME Stock Overview
23andMe Holding Co. operates as a consumer genetics testing company.
23andMe Holding Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.64|
|52 Week High||US$13.68|
|52 Week Low||US$2.12|
|1 Month Change||18.95%|
|3 Month Change||30.94%|
|1 Year Change||-58.16%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-62.86%|
Recent News & Updates
23andMe: Holiday Miracles Not Enough, Growth Path Too Expensive
23andMe is a consumer-facing genetics testing company, one of the largest in terms of genetic databases. However, there are some glaring financial risks to consider if you want to invest in the company: slow test kit growth and profitability. New attempts to move towards drug development and primary care telehealth may drive revenues, it will continue to be unprofitable. For these reasons, I would recommend avoiding the company.
|ME||US Healthcare||US Market|
Return vs Industry: ME underperformed the US Healthcare industry which returned 12.6% over the past year.
Return vs Market: ME underperformed the US Market which returned -12.8% over the past year.
|ME Average Weekly Movement||11.7%|
|Healthcare Industry Average Movement||9.6%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||17.1%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ME is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ME's weekly volatility (12%) has been stable over the past year.
About the Company
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit.
23andMe Holding Fundamentals Summary
|ME fundamental statistics|
Is ME overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ME income statement (TTM)|
|Cost of Revenue||US$138.95m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 08, 2022
|Earnings per share (EPS)||-0.48|
|Net Profit Margin||-79.99%|
How did ME perform over the long term?See historical performance and comparison
Is ME undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ME?
Other financial metrics that can be useful for relative valuation.
|What is ME's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ME's PS Ratio compare to its peers?
|ME PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
MD Pediatrix Medical Group
HIMS Hims & Hers Health
PIII P3 Health Partners
ADUS Addus HomeCare
ME 23andMe Holding
Price-To-Sales vs Peers: ME is expensive based on its Price-To-Sales Ratio (6x) compared to the peer average (1.6x).
Price to Earnings Ratio vs Industry
How does ME's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Sales vs Industry: ME is expensive based on its Price-To-Sales Ratio (6x) compared to the US Healthcare industry average (1.5x)
Price to Sales Ratio vs Fair Ratio
What is ME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||6x|
|Fair PS Ratio||1.7x|
Price-To-Sales vs Fair Ratio: ME is expensive based on its Price-To-Sales Ratio (6x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).
Share Price vs Fair Value
What is the Fair Price of ME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ME's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ME's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
How is 23andMe Holding forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ME is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ME is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ME is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ME's revenue is expected to decline over the next 3 years (-0.01% per year).
High Growth Revenue: ME's revenue is forecast to decline over the next 3 years (-0.01% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ME is forecast to be unprofitable in 3 years.
Discover growth companies
How has 23andMe Holding performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: ME is currently unprofitable.
Growing Profit Margin: ME is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ME's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ME's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ME is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (7.7%).
Return on Equity
High ROE: ME has a negative Return on Equity (-23.75%), as it is currently unprofitable.
Discover strong past performing companies
How is 23andMe Holding's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ME's short term assets ($601.8M) exceed its short term liabilities ($153.2M).
Long Term Liabilities: ME's short term assets ($601.8M) exceed its long term liabilities ($83.2M).
Debt to Equity History and Analysis
Debt Level: ME is debt free.
Reducing Debt: ME has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ME has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ME has sufficient cash runway for 2 years if free cash flow continues to grow at historical rates of 2.9% each year.
Discover healthy companies
What is 23andMe Holding current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ME's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ME's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ME has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ms. Anne Wojcicki had been a Director of Ajax I since October 30, 2020. Ms. Wojcicki serves as a General Partner of Covalence Life Sciences Partners. She serves as Independent Non-Executive Director of Caz...
CEO Compensation Analysis
Compensation vs Market: Anne's total compensation ($USD32.55M) is above average for companies of similar size in the US market ($USD5.42M).
Compensation vs Earnings: Anne's compensation has increased whilst the company is unprofitable.
Experienced Management: ME's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Experienced Board: ME's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11%.
23andMe Holding Co.'s employee growth, exchange listings and data sources
- Name: 23andMe Holding Co.
- Ticker: ME
- Exchange: NasdaqGS
- Founded: 2006
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$1.643b
- Shares outstanding: 451.33m
- Website: https://www.23andme.com
- 23andMe Holding Co.
- 349 Oyster Point Boulevard
- South San Francisco
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/06 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.